KV Pharmaceutical to continue trading on NYSE till March 31, 2010

KV Pharmaceutical Company ( KVa/KVb) (the "Company") received permission from the New York Stock Exchange (the "Exchange") for its securities to continue to trade on the Exchange until March 31, 2010 while the Company prepares its Annual Report on Form 10-K for the Company's fiscal year ended March 31, 2009 (the "2009 Annual Report").

In the event the Company is unable to file the 2009 Annual Report on or prior to March 31, 2010, the Company may request that the Exchange permit the Company's securities to continue to trade on the Exchange until June 17, 2010. In the event the Company is unable to file the 2009 Annual Report prior to June 17, 2010 (or prior to March 31, 2010 in the event the Company requests that the Exchange permit the Company's security to continue to trade on the Exchange until June 17, 2010 and such request is not granted by the Exchange), the Exchange will initiate suspension and delisting procedures.

As previously disclosed by the Company on its Form 12b-25 filed with the SEC on June 2, 2009, as well as in subsequent filings with the SEC, the Company has been unable to file its 2009 Annual Report. The Company's Current Report on Form 8-K filed with the SEC on November 12, 2009 sets forth additional information regarding the Company's inability to timely file the 2009 Annual Report, certain other periodic reports, and related matters.